18,582.500 +708.000 (+3.96%)
Close ARS Disclaimer

AstraZeneca PLC Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
83500
Equity Type
-
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Contact Information
Address
Cambridge,CB2 0AA United Kingdom
Phone
44 20 3749 5000
Fax
-
Top Executives
Name
Age
Since
Title
Pascal Soriot 62 2012 CEO & Executive Director
Aradhana Sarin 47 2021 CFO & Executive Director
Philip Arthur John Broadley 62 2017 Senior Independent Non-Executive Director
Jeffrey Pott 0 2009 CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Menelas Pangalos 56 2013 EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
Deborah DiSanzo Eldracher 63 2017 Independent Non-Executive Director
Shu Kam Mok 61 2019 Independent Non-Executive Director
Nazneen Rahman 55 2017 Independent Non-Executive Director
Rain Henderson 0 0000 Member of External Sustainability Advisory Board
Diana Layfield 51 2020 Independent Non-Executive Director
Sherilyn S. D. McCoy 64 2017 Independent Non-Executive Director
Pankaj Bhatia 0 0000 Member of External Sustainability Advisory Board
Michel Demare 67 2019 Independent Chairman
Polly Courtice 71 0000 Member of External Sustainability Advisory Board
Louise Nicholls 0 0000 Member of External Sustainability Advisory Board
Euan A. Ashley 51 2020 Independent Non-Executive Director
Andreas Rummelt 67 2021 Independent Non-Executive Director
Pam P. Cheng 52 2015 EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles